Group 1 - The innovation drug sector is experiencing increased attention from institutional investors, with significant participation from enterprise annuities and pension funds in newly established ETFs [1][2] - The Industrial Bank of China’s ETF has 95.67% of its shares held by institutional investors, with enterprise annuities dominating the top holders [1] - Major state-owned banks' enterprise annuities are among the top holders, with significant shares exceeding 40 million [1][2] Group 2 - The performance of innovation drug ETFs has been strong, with several funds showing over 25% growth year-to-date [3] - Fund managers are optimistic about the innovation drug sector, indicating a structural change in the market and increased allocations to CRO and CDMO sectors [3][4] - The implementation of new drug registration regulations has shortened approval times, leading to a predicted significant performance release in the innovation drug industry by 2025 [4]
企业年金密集出手大举加码创新药ETF
Shang Hai Zheng Quan Bao·2025-03-31 18:38